QSAM - InvestorNewsBreaks - QSAM Biosciences Inc. (QSAM) Issues Update on Progress Preliminary Clinical Data for Phase 1 CycloSam(R) Trial
QSAM Biosciences (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (“CycloSam(R)”), for the treatment of bone cancer and related diseases, today issued a letter to its shareholders. In the letter, the company’s Executive Chairman C. Richard Piazza and CEO Douglas Baum, who are also co-founders of QSAM, provided an update on the progress and preliminary data from the phase 1 trial studying the safety and early signs of efficacy of CycloSam(R) in patients with cancer that has metastasized to the bone from the breast, lung, prostate and other organs. They also outlined important goals for QSAM Biosciences through the end of the year as well as the strategy to seek capital to fund the company’s plans. The update reads, “We look forward to more progress in the second half of 2023, which we expect will continue to de-risk our technology and create value for our shareholders. We are confident in our team, our technology, and our ability to advance CycloSam(R) through the FDA process. Ultimately, however, our primary mission is to help the hundreds of thousands of adults and children each year suffering from bone cancer.”
To view the full press release, visit https://ibn.fm/YyKoA
About QSAM Biosciences Inc.
QSAM Biosciences is developing next-generation nuclear medicines for the treatment of cancer and other diseases. QSAM’s initial technology, CycloSam(R) (Samarium-153 DOTMP), is a clinical-stage bone-targeting radiopharmaceutical developed by IsoTherapeutics Group LLC, pioneers in the nuclear medicine space who also developed the FDA-approved Quadramet(R) (Samarium-153 EDTMP), which is indicated for bone cancer pain palliation. QSAM is led by an experienced executive team and board of directors that have completed numerous FDA approvals and multiple successful biotech exits. For more information, visit the company’s website at https://QSAMBio.com.
NOTE TO INVESTORS: The latest news and updates relating to QSAM are available in the company’s newsroom at http://ibn.fm/QSAM
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.